Skip to content
OpenCapital
Get started

Pfizer PFE Biopharma — Provision

Similar metrics at other companies

Royalty Pharma logo
RPRXProvision (benefit) for other credit losses
-$197.49M-55.3%
Constellium logo
CSTMProvisions
$101M+9.8%
Old National Bancorp logo
ONBProvision (release)
$34.95M+11.3%
Vertex Pharmaceuticals logo
VRTXPharmaceuticals — Provision for income taxes
$221.5M+163%
Blackstone Mortgage Trust logo
BXMTProvision (release)
$55.06M+11.2%
Organon logo
OGNU.S. — Provision
$861.75M+14.0%

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$143.68B+11.1%
Enterprise value$206.35B+9.2%
P/E11.9×—
P/S2.3×+0.2×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:RestructuringCharges.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's biopharma — provision.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's biopharma — provision?
Pfizer (PFE) reported biopharma — provision of $47M in Q1 2026.
How has Pfizer's biopharma — provision changed year-over-year?
Pfizer's biopharma — provision decreased by 92.4% year-over-year, from $617M to $47M.
What is the long-term trend for Pfizer's biopharma — provision?
Over 3 years (2022 to 2025), Pfizer's biopharma — provision has grown at a 49.9% compound annual growth rate (CAGR), from $796M to $2.68B.
What does biopharma — provision mean?
Refers to the estimated amount set aside for specific liabilities or tax obligations related to the biopharmaceutical segment's operations. This reflects management's assessment of potential future outflows that are probable and estimable.